TG Therapeutics Inc 2026年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS,INC. (Exact name of registrant as specified in its charter) Delaware36-3898269(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 3020 Carrington Mill Blvd, Suite 475Morrisville, North Carolina 27560(Address including zip code of principal executive offices) (877) 575-8489(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Actof 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subjectto such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was requiredto submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒ Accelerated filer☐ Smaller reporting company☐ Non-accelerated filer☐ Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ Table of Contents TG THERAPEUTICS,INC.FORM10-QFOR THE QUARTER ENDEDMARCH 31, 2026TABLE OF CONTENTSSPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS3SUMMARY RISK FACTORS4PARTIFINANCIAL INFORMATION6Item1Financial Statements:6Condensed Consolidated Balance Sheets6Condensed Consolidated Statements of Operations (unaudited)7Condensed Consolidated Statements of Changes in Stockholders’Equity (unaudited)8Condensed Consolidated Statements of Cash Flows (unaudited)9Notesto Condensed Consolidated Financial Statements (unaudited)10Item2Management’s Discussion and Analysis of Financial Condition and Results of Operations29Item3Quantitative and Qualitative Disclosures About Market Risk37Item4Controls and Procedures37PARTIIOTHER INFORMATION38Item1Legal Proceedings38Item1ARisk Factors38Item 2Unregistered Sales of Equity Securities and Use of Proceeds89Item 3Defaults of Senior Securities89Item 4Mine Safety Disclosures89Item 5Other Information89Item6Exhibits90 SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain matters discussed in this QuarterlyReport on Form 10-Qcontain forward-looking statements. All statements other thanstatements of historical factsmay constitute forward-looking statements. We intend such forward-looking statements to be subject to the safeharbor provisions of the Private Securities Litigation Reform Act of 1995, including Section 27A of the Securities Act of 1933, as amended(Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Forward-looking statements involveknown and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materiallydifferent from the future results, performance or achievements expressed or implied by such forward-looking statements. In some cases, you canidentify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,”“may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would” or the negative of these words or other comparableterminology, although not all forward-looking statements contain these identifying words. All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by these cautionary statements.Such forward-looking statements include, but are not limited to, statements about: ●our ability to obtain regulatory approvals for our product candidatesand our ability to maintain regulatory approval of BRIUMVI®(ublituximab-xiiy)150 mg/6 mL Injection for intravenous therapyfor the treatment of relapsing forms of multiple sclerosis (RMS) or anyother future indication in